TMDX

Companies
NASDAQ
TransMedics Group Inc.
Health Care
Price Chart
Overview

About TMDX

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Market Cap
$4.5B
Volume
122.3M
Avg. Volume
135.0M
P/E Ratio
41.181816
Dividend Yield
0.00%
Employees
375.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Medical Devices
Risk & Correlation Analysis
Market Correlation
1.59
High Correlation
Volatility
High (0.73)
Relative to market

Macro Factor Sensitivities

Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for TMDX.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, TMDX shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$4.5B
Volume122.3M
P/E Ratio41.18
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
February 28, 2025

PortfolioPilot Analysis

Get AI-powered insights on how TMDX fits into your investment strategy and portfolio diversification.

Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025